EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Differential Radiobiological Effects of Alpha- and Beta-Minus-Emitter Targeted Radionuclide Therapy: DNA Damage and Survival

Ruth C Winter, Ulrike Bauder-Wüst, Martin Schäfer, Yvonne Remde, Mareike Roscher, Ramon Lopez Perez, Martina Benešová-Schäfer

International Journal of Radiation Oncology*Biology*Physics · 2026

DOI: 10.1016/j.ijrobp.2026.08.036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026. Verfasst von Ruth C Winter und 6 weiteren Autor:innen. Beteiligte Einrichtung: Junior Research Group Translational Radiotheranostics, German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Physics and Astronomy, H…. Hauptthemen laut MEDLINE: Alpha Particles, Prostatic Neoplasms, Radioisotopes, Beta Particles. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Metastatic cancer remains a major challenge, demanding more effective and biologically informed therapeutic strategies. Targeted radionuclide therapy (TRT) holds significant promise, but limited understanding of treatment response and resistance hinders its optimization. This work aimed to improve TRT efficacy and overcome radioresistance by determining how radionuclide properties, administered activity, and subcellular localization govern radiobiological outcomes. The objectives were to advance TRT for prostate cancer, overcome radioresistance, and generate mechanistic insights to guide radiopharmaceutical design and radionuclide selection. METHODS AND MATERIALS: Prostate-specific membrane antigen (PSMA)-positive (LNCaP [lymph node adenocarcinoma of the prostate] and C4-2) and PSMA-negative (PC-3) prostate cancer cell lines were exposed to 225Ac- or 177Lu-labeled PSMA radiopharmaceuticals or nontargeted radionuclides for 1 or 4 hours across activity ranges for α-emitters (1-100 kBq) and β⁻-emitters (100-5000 kBq), with external beam radiation therapy (0.5-2.5 Gy) as a reference. DNA double‑strand breaks (DSBs) were quantified by immunofluorescence‑based γH2AX analysis and complemented by cell viability assays. A proof‑of‑concept combination study with the DNA-dependent protein kinase (DNA-PK) inhibitor Nedisertib (M3814; Selleck Chemicals, Houston, TX, USA) was performed. RESULTS: The α-emitters outperformed the β⁻-emitters, inducing comparable DSBs at only 1% of the applied activity. PSMA‑mediated internalization strongly enhanced short‑range α‑TRT but had negligible impact on longer‑range β⁻‑TRT. α‑Induced DSBs persisted for up to 72 hours, whereas DSBs decreased over time after β⁻‑TRT and external beam radiation therapy. Combination therapy with Nedisertib significantly enhanced TRT efficacy in C4-2 cells, enabling a 64‑fold (225Ac) versus 4‑fold (177Lu) reduction in required activity. In the least radiosensitive PC-3 cells, viability decreased to below 50% following combined α-TRT and Nedisertib treatment. CONCLUSIONS: Our study defines key determinants for optimizing TRT. Cellular internalization is critical for short-range α-emitters, whereas β⁻-emitters depend on high binding affinity and retention, providing experimental guidance for radiopharmaceutical design and radionuclide selection. Distinct DNA repair kinetics underscore radionuclide‑specific biological effects. Combining TRT with DNA‑PK inhibition is a promising strategy to enhance efficacy, enable activity de‑escalation, and potentially mitigate toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alpha ParticlesProstatic NeoplasmsRadioisotopesBeta ParticlesDNA DamageRadiation ToleranceRadiopharmaceuticalsDNA Breaks, Double-StrandedHumansCell SurvivalActiniumCell Line, TumorMaleAntigens, SurfaceLutetiumHistonesGlutamate Carboxypeptidase IIPC-3 Cells

Substanzen

RadioisotopesActiniumRadiopharmaceuticalsAntigens, SurfaceLutetiumActinium-225Lutetium-177HistonesGlutamate Carboxypeptidase IIFOLH1 protein, human

Autor:innen und Institutionen

  • Junior Research Group Translational Radiotheranostics, German Cancer Research Center (DKFZ), Heidelberg, Germany; Faculty of Physics and Astronomy, Heidelberg University, Heidelberg, Germany.
  • Junior Research Group Translational Radiotheranostics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Service Unit Radiopharmaceuticals and Preclinical Studies, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Clinical Cooperation Unit Molecular and Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Junior Research Group Translational Radiotheranostics, German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: m.benesova@dkfz-heidelberg.de.

Förderung

  • Bayer

Zitieren

APA

Winter, R. C., Bauder-Wüst, U., Schäfer, M., Remde, Y., Roscher, M., Perez, R. L., & Benešová-Schäfer, M. (2026). Differential Radiobiological Effects of Alpha- and Beta-Minus-Emitter Targeted Radionuclide Therapy: DNA Damage and Survival. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2026.08.036

Vancouver

Winter RC, Bauder-Wüst U, Schäfer M, Remde Y, Roscher M, Perez RL, et al. Differential Radiobiological Effects of Alpha- and Beta-Minus-Emitter Targeted Radionuclide Therapy: DNA Damage and Survival. International Journal of Radiation Oncology*Biology*Physics. 2026. doi:10.1016/j.ijrobp.2026.08.036

BibTeX
@article{Winter2026,
  author = {Winter, Ruth C and Bauder-Wüst, Ulrike and Schäfer, Martin and Remde, Yvonne and Roscher, Mareike and Perez, Ramon Lopez and Benešová-Schäfer, Martina},
  title = {Differential Radiobiological Effects of Alpha- and Beta-Minus-Emitter Targeted Radionuclide Therapy: DNA Damage and Survival},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  doi = {10.1016/j.ijrobp.2026.08.036}
}
Kostenlos starten →